Комбинированное лечение операбельного рака молочной железы с использованием интраоперационной лучевой терапии

Комбинированное лечение операбельного рака молочной железы с использованием интраоперационной лучевой терапии

Автор: Алайчиев Н.А., Усынин Е.А., Кондакова И.В., Середа Е.Е., Фролова И.Г., Дорошенко А.В., Гарбуков Е.Ю., Старцева Ж.А.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 1 т.22, 2023 года.

Бесплатный доступ

Цель исследования - изучить литературные данные, посвященные эффективности комбинированного лечения с использованием интраоперационной лучевой терапии (ИОЛТ) у больных операбельным раком молочной железы (РМЖ). Материал и методы. По теме найдено 110 зарубежных и российских публикаций (2000-21 гг.), представленных в базах данных Scopus, Pubmed, Elibrary и других, ключе-выми словами поиска явились: рак молочной железы, местный рецидив, интраоперационная лучевая терапия и методика облучения. Более значимые из них (45) включены в данный литературный обзор. Результаты. Лучевая терапия занимает важнейшее место в программе органосохраняющего лечения РМЖ. Многочисленными рандомизированными исследованиями за рубежом и в России было показано, что применение послеоперационной лучевой терапии резко уменьшает число локорегионарных рецидивов. Использование ИОЛТ как эффективного метода профилактики рецидивов по сравнению со стандартной послеоперационной адъювантной лучевой терапией является важным направлением в радиационной онкологии. Заключение. Таким образом, использование ИОЛТ в комбинированном лечении операбельного РМЖ должно быть дифференцировано и основано на совокупности клинико-морфологических факторов прогноза заболевания. Так, для различных молекулярных подтипов РМЖ характерны значительные отличия в патогенезе и ответе на проводимую терапию. Актуальным остается дальнейшее изучение эффективности ИОЛТ с целью выделения группы пациенток с абсолютными показаниями для проведения указанной методики.

Еще

Рак молочной железы, органосохраняющая операция, рецидив, интраоперационнная лучевая терапия

Короткий адрес: https://sciup.org/140297835

IDR: 140297835   |   DOI: 10.21294/1814-4861-2023-22-1-119-127

Список литературы Комбинированное лечение операбельного рака молочной железы с использованием интраоперационной лучевой терапии

  • Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020; 70(4): 313.
  • Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2020 godu. M., 2021. 239 s.
  • Boyages J., Baker L. Evolution of radiotherapy techniques in breast conservation treatment. Gland Surg. 2018; 7(6): 576-95. https://doi.org/10.21037/gs.2018.11.10.
  • Kunkler I.H., Williams L.J., Jack W.J., Cameron D.A., Dixon J.M.; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015; 16(3): 266-73. https://doi.org/10.1016/S1470-2045(14)71221-5. Erratum in: Lancet Oncol. 2015; 16(3).
  • Smith B.D., Bellon J.R., Blitzblau R., Freedman G., Haffty B., Hahn C., Halberg F., Hoffman K., Horst K., Moran J., Patton C., Perlmutter J., Warren L., Whelan T., Wright J.L., Jagsi R. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018; 8(3): 145-52. https://doi.org/10.1016/j.prro.2018.01.012.
  • Fisher E.R., Anderson S., Tan-Chiu E., Fisher B., Eaton L., Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001; 91(8 s): 1679-87.
  • Veronesi U., Marubini E., Del Vecchio M., Manzari A., Andreola S., Greco M., Luini A., Merson M., Saccozzi R., Rilke F. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995; 87(1): 19-27. https://doi.org/10.1093/jnci/87.1.19.
  • Veronesi U., Marubini E., Mariani L., Galimberti V., Luini A., Veronesi P., Salvadori B., Zucali R. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001; 12(7): 997-1003. https://doi.org/10.1023/a:1011136326943.
  • Gage I., Recht A., Gelman R., Nixon A.J., Silver B., Bornstein B.A., Harris J.R. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995; 33(2): 245-51. https://doi.org/10.1016/0360-3016(95)02001-R.
  • Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., Jeong J.H., Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16): 1233-41. https://doi.org/10.1056/NEJMoa022152.
  • Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans V., Godwin J., Gray R., Hicks C., James S., MacKinnon E., McGale P., McHugh T., Peto R., Taylor C., Wang Y.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503): 2087-106. https://doi.org/10.1016/S0140-6736(05)67887-7.
  • Smith B.D., Bentzen S.M., Correa C.R., Hahn C.A., Hardenbergh P.H., Ibbott G.S., McCormick B., McQueen J.R., Pierce L.J., Powell S.N., Recht A., Taghian A.G., Vicini F.A., White J.R., Haffty B.G. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011; 81(1): 59-68. https://doi.org/10.1016/j.ijrobp.2010.04.042.
  • Haviland J.S., Owen J.R., Dewar J.A., Agrawal R.K., Barrett J., Barrett-Lee P.J., Dobbs H.J., Hopwood P., Lawton P.A., Magee B.J., Mills J., Simmons S., Sydenham M.A., Venables K., Bliss J.M., Yarnold J.R.; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086-94. https://doi.org/10.1016/S1470-2045(13)70386-3.
  • Kindts I., Laenen A., Depuydt T., Weltens C. Tumour bed boost radiotherapy for women after breast-conserving surgery. Cochrane Database Syst Rev. 2017; 11(11). https://doi.org/10.1002/14651858.CD011987.pub2.
  • Bartelink H., Maingon P., Poortmans P., Weltens C., Fourquet A., Jager J., Schinagl D., Oei B., Rodenhuis C., Horiot J.C., Struikmans H., Van Limbergen E., Kirova Y., Elkhuizen P., Bongartz R., Miralbell R., Morgan D., Dubois J.B., Remouchamps V., Mirimanoff R.O., Collette S., Collette L.; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015; 16(1): 47-56. https://doi.org/10.1016/S1470-2045(14)71156-8. Erratum in: Lancet Oncol. 2015; 16(1).
  • Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., Van den Bogaert W., Fourquet A., Jager J.J., Hoogenraad W.J., Oei S.B., WárlámRodenhuis C.C., Pierart M., Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22): 3259-65. https://doi.org/10.1200/JCO.2007.11.4991.
  • Smith B.D., Arthur D.W., Buchholz T.A., Haffty B.G., Hahn C.A., Hardenbergh P.H., Julian T.B., Marks L.B., Todor D.A., Vicini F.A., Whelan T.J., White J., Wo J.Y., Harris J.R. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009; 74(4): 987-1001. https://doi.org/10.1016/j.ijrobp.2009.02.031.
  • Correa C., Harris E.E., Leonardi M.C., Smith B.D., Taghian A.G., Thompson A.M., White J., Harris J.R. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017; 7(2): 73-9. https://doi.org/10.1016/j.prro.2016.09.007.
  • Polgár C., Van Limbergen E., Pötter R., Kovács G., Polo A., Lyczek J., Hildebrandt G., Niehoff P., Guinot J.L., Guedea F., Johansson B., Ott O.J., Major T., Strnad V.; GEC-ESTRO breast cancer working group. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GECESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010; 94(3): 264-73. https://doi.org/10.1016/j.radonc.2010.01.014.
  • Pierquin B., Dutreix A., Paine C.H., Chassagne D., Marinello G., Ash D. The Paris system in interstitial radiation therapy.Acta Radiol Oncol Radiat Phys Biol. 1978; 17(1): 33-48. https://doi.org/10.3109/02841867809127689.
  • Strnad V., Major T., Polgar C., Lotter M., Guinot J.L., GutierrezMiguelez C., Galalae R., Van Limbergen E., Guix B., Niehoff P., Lössl K., Hannoun-Levi J.M. ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost GEC-ESTRO Breast Cancer Working Group practical recommendations. Radiother Oncol. 2018; 128(3): 411-20. https://doi.org/10.1016/j.radonc.2018.04.009.
  • Hickey B.E., Lehman M., Francis D.P., See A.M. Partial breast irradiation for early breast cancer. Cochrane Database Syst Rev. 2016; 7(7). https://doi.org/10.1002/14651858.CD007077.pub3. Update in: Cochrane Database Syst Rev. 2021; 8.
  • Strnad V., Ott O.J., Hildebrandt G., Kauer-Dorner D., Knauerhase H., Major T., Lyczek J., Guinot J.L., Dunst J., Gutierrez Miguelez C., Slampa P., Allgäuer M., Lössl K., Polat B., Kovács G., Fischedick A.R., Wendt T.G., Fietkau R., Hindemith M., Resch A., Kulik A., Arribas L., Niehoff P., Guedea F., Schlamann A., Pötter R., Gall C., Malzer M., Uter W., Polgár C.; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016; 387(10015): 229-38. https://doi.org/10.1016/S0140-6736(15)00471-7.
  • Suralik G., Rudra S., Dutta S.W., Yu J., Sanders J.C., Schad M.D., Janowski E.M., Su L., Libby B., Showalter S.L., Lobo J.M., Showalter T.N. Time-driven activity-based costing of a novel form of CT-guided high-doserate brachytherapy intraoperative radiation therapy compared with conventional breast intraoperative radiation therapy for early stage breast cancer. Brachytherapy. 2020; 19(3): 348-54. https://doi.org/10.1016/j.brachy.2020.02.005.
  • Budrukkar A., Pandit P., Wadasadawala T., Upreti R.R., Jalali R., Gupta S., Shet T., Parmar V., Badwe R., Sarin R. Impact of adjuvant systemic chemotherapy on wound healing and cosmetic outcome in 224 women treated with accelerated partial breast irradiation using interstitial brachytherapy. Brachytherapy. 2017; 16(5): 935-42. https://doi.org/10.1016/j.brachy.2017.06.005.
  • Tsai P.I., Ryan M., Meek K., Ryoo M.C., Tome M., Takasugi J., Haigh P., Difronzo L.A. Accelerated partial breast irradiation using the MammoSite device: early technical experience and short-term clinical follow-up. Am Surg. 2006; 72(10): 929-34. https://doi.org/10.1177/000313480607201020.
  • Nairz O., Deutschmann H., Kopp M., Wurstbauer K., Kametriser G., Fastner G., Merz F., Reitsamer R., Menzel C., Sedlmayer F. A dosimetric comparison of IORT techniques in limited-stage breast cancer. Strahlenther Onkol. 2006; 182(6): 342-8. https://doi.org/10.1007/s00066-006-1580-2.
  • Shah N.M., Tenenholz T., Arthur D., DiPetrillo T., Bornstein B., Cardarelli G., Zheng Z., Rivard M.J., Kaufman S., Wazer D.E. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis. Cancer. 2004; 101(4): 727-34. https://doi.org/10.1002/cncr.20424.
  • Jozsef G., Luxton G., Formenti S.C. Application of radiosurgery principles to a target in the breast: a dosimetric study. Med Phys. 2000; 27(5): 1005-10. https://doi.org/10.1118/1.598965.
  • Vicini F.A., Cecchini R.S., White J.R., Arthur D.W., Julian T.B., Rabinovitch R.A., Kuske R.R., Ganz P.A., Parda D.S., Scheier M.F., Winter K.A., Paik S., Kuerer H.M., Vallow L.A., Pierce L.J., Mamounas E.P., McCormick B., Costantino J.P., Bear H.D., Germain I., Gustafson G., Grossheim L., Petersen I.A., Hudes R.S., Curran W.J. Jr, Bryant J.L., Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019; 394(10215): 2155-64. https://doi.org/10.1016/S0140-6736(19)32514-0.
  • Veronesi U., Orecchia R., Luini A., Galimberti V., Gatti G., Intra M., Veronesi P., Leonardi M.C., Ciocca M., Lazzari R., Caldarella P., Simsek S., Silva L.S., Sances D. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg. 2005; 242(1): 101-6. https://doi.org/10.1097/01.sla.0000167927.82353.bc.
  • Vaidya J.S., Baum M., Tobias J.S., Morgan S., D’Souza D. The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer. Eur J Surg Oncol. 2002; 28(4): 447-54. https://doi.org/10.1053/ejso.2002.1275.
  • Holland R., Connolly J.L., Gelman R., Mravunac M., Hendriks J.H., Verbeek A.L., Schnitt S.J., Silver B., Boyages J., Harris J.R. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol. 1990; 8(1): 113-8. https://doi.org/10.1200/JCO.1990.8.1.113.
  • Benda R.K., Yasuda G., Sethi A., Gabram S.G., Hinerman R.W., Mendenhall N.P. Breast boost: are we missing the target? Cancer. 2003; 97(4): 905-9. https://doi.org/10.1002/cncr.11142.
  • Poortmans P.M., Collette L., Horiot J.C., Van den Bogaert W.F., Fourquet A., Kuten A., Noordijk E.M., Hoogenraad W., Mirimanoff R.O., Pierart M., van Limbergen E., Bartelink H.; EORTC Radiation Oncology and Breast Cancer Groups. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol. 2009; 90(1): 80-5. https://doi.org/10.1016/j.radonc.2008.07.011.
  • Sedlmayer F., Reitsamer R., Wenz F., Sperk E., Fussl C., Kaiser J., Ziegler I., Zehentmayr F., Deutschmann H., Kopp P., Fastner G. Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol. 2017; 12(1): 23. https://doi.org/10.1186/s13014-016-0749-9.
  • Vaidya J.S., Bulsara M., Baum M., Wenz F., Massarut S., Pigorsch S., Alvarado M., Douek M., Saunders C., Flyger H.L., Eiermann W., BrewGraves C., Williams N.R., Potyka I., Roberts N., Bernstein M., Brown D., Sperk E., Laws S., Sütterlin M., Corica T., Lundgren S., Holmes D., Vinante L., Bozza F., Pazos M., Le Blanc-Onfroy M., Gruber G., Polkowski W., Dedes K.J., Niewald M., Blohmer J., McCready D., Hoefer R., Kelemen P., Petralia G., Falzon M., Joseph D.J., Tobias J.S. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ. 2020; https://doi.org/10.1136/bmj.m2836.
  • Orecchia R., Veronesi U., Maisonneuve P., Galimberti V.E., Lazzari R., Veronesi P., Jereczek-Fossa B.A., Cattani F., Sangalli C., Luini A., Caldarella P., Venturino M., Sances D., Zurrida S., Viale G., Leonardi M.C., Intra M. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021; 22(5): 597-608. https://doi.org/10.1016/S1470-2045(21)00080-2.
  • Wenz F. First Outcome Analysis of the TARGIT E (Elderly) Trial- Prospective Phase 2 Study of Intraoperative Radiation Therapy (IORT) in Elderly Patients With Small Breast Cancer. Int J Rad Oncol Biol Phys. 2016; 96(2). https://doi.org/10.1016/j.ijrobp.2016.06.616.
  • Vaidya J.S., Bulsara M., Baum M., Alvarado M., Bernstein M., Massarut S., Saunders C., Sperk E., Wenz F., Tobias J.S.; TARGIT-A investigators. Intraoperative radiotherapy for breast cancer: powerful evidence to change practice. Nat Rev Clin Oncol. 2021; 18(3): 187-8. https://doi.org/10.1038/s41571-021-00471-7.
  • Silverstein M.J., Fastner G., Maluta S., Reitsamer R., Goer D.A., Vicini F., Wazer D. Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 1--ELIOT. Ann Surg Oncol. 2014; 21(12): 3787-92. https://doi.org/10.1245/s10434-014-3998-6.
  • Fastner G., Reitsamer R., Gaisberger C., Hitzl W., Urbański B., Murawa D., Matuschek C., Budach W., Ciabattoni A., Reiland J., Molnar M., Vidali C., Schumacher C., Sedlmayer F., on behalf of the HIOB Trialist Group. Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459). Cancers (Basel). 2022; 14(6): 1396. https://doi.org/10.3390/cancers14061396.
  • Chumachenko I.S., Murashko R.A., Keshabyan A.A., Krivorot'ko P.V., Novikov S.N. Rezul'taty organosokhranyayushchego lecheniya raka molochnoi zhelezy s primeneniem intraoperatsionnoi luchevoi terapii. Opukholi zhenskoi reproduktivnoi sistemy. 2021; 17(3): 16-23. https://doi.org/10.17650/1994-4098-2021-17-3-16-23.
  • Manikhas A.G., Gor L.A., Topuzov E.E., Oganesyan A.S., Fedorova O.I., Kalinin I.V. Opyt primeneniya intraoperatsionnoi luchevoi terapii u patsientok s rannim rakom molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2022; 18(2): 14-20. https://doi.org/10.17650/1994-4098-2022-18-2-14-20.
  • Doroshenko A.V., Slonimskaya E.M., Startseva Zh.A., Lisin V.A., Garbukov E.Yu., Tarabanovskaya N.A., Kokorina Yu.L., Litvyakov N.V. Desyatiletnie rezul'taty organosokhranyayushchego lecheniya raka molochnoi zhelezy s primeneniem intraoperatsionnoi luchevoi terapii. Sibirskii onkologicheskii zhurnal. 2017; 16(6): 11-7. https://doi.org/10.21294/1814-4861-2017-16-6-11-17.
Еще
Статья научная
SciUp 2024 © 2024 ©